DBV Technologies SA Sponsored ADR

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monthly information regarding the total number of voting rights and 

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

The company provided a grim business update.

Why DBV Technologies Is Plunging Today

DBV Technologies Provides Operational and Business Update

Monthly information regarding the total number of voting rights and   total number of shares of the Company as of May 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Information regarding the total number of voting rights and   total number of shares of the Company as of April 30, 2020

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2020

Aimmune Therapeutics

Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies

DBV Technologies Reports March 31, 2020 Cash Position

DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

DBV Technologies: Don't Panic - The Good, The Bad, And The Opportunity

Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

Ordinary and Extraordinary General Meeting of April 20, 2020

DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

Monthly information regarding the total number of voting rights and   total number of shares of the Company as of February 29, 2020 and March 4, 2020

DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering

DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)

DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

News for DBV Technologies SA Sponsored ADR Stock (DBVT)